Relation of Characteristics of Metabolic Syndrome to Short-Term Prognosis and Effects of Intensive Statin Therapy After Acute Coronary Syndrome
- 1 October 2005
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 28 (10) , 2508-2513
Abstract
OBJECTIVE—We examined relations between characteristics of the metabolic syndrome, early cardiovascular risk, and effect of early, intensive statin therapy after acute coronary syndrome. RESEARCH DESIGN AND METHODS—A total of 3,038 patients in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial were characterized by the presence or absence of a history of diabetes, a history of hypertension and/or blood pressure ≥130/≥85, BMI >30 kg/m2, HDL cholesterol n = 1,161) met criteria for metabolic syndrome as defined in this study and had a 19% incidence of a primary end point event (death, nonfatal myocardial infarction, cardiac arrest, or recurrent unstable myocardial ischemia) during the 16-week trial. Patients with two or fewer characteristics (n = 1,877) were classified as not having metabolic syndrome and had a 14% incidence of a primary end point event. In univariate analysis, the individual characteristics that bore a significant relation to risk were diabetes and low HDL cholesterol. In a multivariable model including age, sex, and randomized treatment assignment, presence of metabolic syndrome was associated with a hazard ratio of 1.49 (95% CI 1.24–1.79, P < 0.0001). Relative risk reduction with 80 mg atorvastatin daily compared with placebo was similar in patients with and without metabolic syndrome. CONCLUSIONS—Metabolic syndrome, as defined in the context of this clinical trial, is a strong predictor of early recurrent ischemic events after acute coronary syndrome.Keywords
This publication has 29 references indexed in Scilit:
- Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular diseaseAmerican Heart Journal, 2005
- Hyperinsulinaemia is associated with increased long-term mortality following acute myocardial infarction in non-diabetic patients?European Heart Journal, 2004
- Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromesAmerican Heart Journal, 2004
- Body Mass IndexCirculation, 2003
- Hospital and 1-year outcome after acute myocardial infarction in patients with diabetes mellitus and hypertensionJournal of Human Hypertension, 2003
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- The prognostic significance of a history of systemic hypertension in patients randomised to either placebo or ramipril following acute myocardial infarction: evidence from the AIRE studyJournal of Human Hypertension, 1999
- Elevated glycated haemoglobin in non-diabetic patients is associated with an increased mortality in myocardial infarctionPostgraduate Medical Journal, 1998
- Long-term prognosis after acute myocardial infarction in patients with a history of arterial hypertensionEuropean Heart Journal, 1998
- Banting lecture 1988. Role of insulin resistance in human diseaseDiabetes, 1988